| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Cell Assay |
- Human Intestinal Flora Preparation: Collect fresh fecal samples from healthy volunteers. Dilute the fecal samples with sterile physiological saline (0.9% NaCl) at a ratio of 1:10 (w/v), and homogenize the mixture. Centrifuge the homogenate at a low speed (specific speed not specified in the article) to remove large particulate matter, and the supernatant is used as the intestinal flora suspension. [1]
- Incubation System Setup: Prepare the culture medium (composition includes peptone, yeast extract, glucose, and other nutrients) and sterilize it. Add the intestinal flora suspension (10% v/v) and Isorhamnetin-3-O-glucoside (final concentration not specified in the article) to the sterilized medium. Set up a control group without Isorhamnetin-3-O-glucoside for comparison. [1] - Culture and Sample Collection: Incubate the culture system at 37°C under anaerobic conditions (using an anaerobic incubator with 85% N₂, 10% H₂, and 5% CO₂). Collect 1 mL of the culture solution at different time points (0 h, 6 h, 12 h, 24 h, 48 h). Add an equal volume of methanol to the collected samples to terminate the reaction, vortex thoroughly, and centrifuge at a high speed (specific speed not specified in the article) to obtain the supernatant. [1] - Metabolite Detection: Filter the supernatant through a 0.22 μm microporous membrane. Analyze the filtered samples using UPLC/Q-TOF MS. The UPLC conditions include a C18 chromatographic column, gradient elution with mobile phases (water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid), and a flow rate of 0.3 mL/min. The Q-TOF MS is operated in positive ion mode to detect and identify the metabolites of Isorhamnetin-3-O-glucoside. [1] |
|---|---|
| ADME/Pharmacokinetics |
In vitro, isorhamnetin-3-O-glucoside can be metabolized by human gut microbiota. Its main metabolic pathways include deglycosylation (removal of the glucose portion) to generate isorhamnetin, followed by demethylation of isorhamnetin to generate quercetin, and further hydrogenation of quercetin to generate dihydroquercetin. [1]
- The metabolites of isorhamnetin-3-O-glucoside (including isorhamnetin, quercetin and dihydroquercetin) were identified and quantified by ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF MS). Mass spectrometry data (molecular weight, fragment ions) were used to confirm the chemical structure of each metabolite. [1] During 48 hours of in vitro culture with human gut microbiota, the concentration of isorhamnetin-3-O-glucoside gradually decreased, while the concentrations of its metabolites (isorhamnetin, quercetin, and dihydroquercetin) first increased and then stabilized, indicating that the metabolism of this compound reached dynamic equilibrium within 48 hours. [1] |
| References | |
| Additional Infomation |
Isorhamnetin 3-O-β-D-glucopyranoside is a glycosyloxyflavonoid, a compound in which isorhamnetin is substituted at the 3-position with a β-D-glucose moiety. It is a metabolite. It is a monosaccharide derivative, a glycosyloxyflavonoid, a monomethoxyflavonoid, a trihydroxyflavonoid, and a β-D-glucopyranoside. Functionally, it is associated with both isorhamnetin and β-D-glucose. Isorhamnetin-3-O-glucopyranoside has been reported in Anoectochilus formosanus, Halocnemum strobilaceum, and other organisms with relevant data. Isorhamnetin-3-O-glucopyranoside is a metabolite found in or produced by Saccharomyces cerevisiae. See also: Ginkgo (partial).
- Isorhamnoside-3-O-glucoside is a flavonoid glycoside widely found in plants such as Ginkgo biloba, Hippophae rhamnoides, and citrus fruits. It is a natural bioactive compound that has attracted much attention due to its potential health benefits. [1] - In vitro studies on the metabolism of isorhamnoside-3-O-glucoside in the human gut microbiota are of great significance. Gut microbiota-mediated metabolism can convert the parent compound into metabolites with different biological activities, which provides a basis for further research on the in vivo absorption and biological effects of isorhamnoside-3-O-glucoside. [1] - The UPLC/Q-TOF MS technique used in this study has high sensitivity and high resolution, which can accurately identify the structure of isorhamnoside-3-O-glucoside metabolites and quantify their relative content, thus ensuring the reliability of the metabolic analysis results. [1] |
| Molecular Formula |
C22H22O12
|
|---|---|
| Molecular Weight |
478.4029
|
| Exact Mass |
478.111
|
| CAS # |
5041-82-7
|
| PubChem CID |
5318645
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
834.4±65.0 °C at 760 mmHg
|
| Melting Point |
155-160ºC
|
| Flash Point |
291.3±27.8 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.750
|
| LogP |
1.71
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
773
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
CQLRUIIRRZYHHS-LFXZADKFSA-N
|
| InChi Code |
InChI=1S/C22H22O12/c1-31-12-4-8(2-3-10(12)25)20-21(17(28)15-11(26)5-9(24)6-13(15)32-20)34-22-19(30)18(29)16(27)14(7-23)33-22/h2-6,14,16,18-19,22-27,29-30H,7H2,1H3/t14-,16-,18+,19-,22+/m1/s1
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~522.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0903 mL | 10.4515 mL | 20.9030 mL | |
| 5 mM | 0.4181 mL | 2.0903 mL | 4.1806 mL | |
| 10 mM | 0.2090 mL | 1.0452 mL | 2.0903 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
